Method of treating inflammation in the joints of a body

• US 20020107188A1
• Filed: 02/02/2001
• Published: 08/08/2002
• Est. Priority Date: 05/10/2000
• Status: Active Grant

• Current Assignee: Allan R. Dunn
• Original Assignee: Allan R. Dunn
• Inventors: Dunn, Allan R.
• Granted Patent: US 6,645,485 B2
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: Y10S 530/84 Bones; tendons; teeth; cartilage

Abstract

A process for treating inflammation in a joint whether heat, redness, pain, swelling and/or stiffness, and for increasing motion and increasing joint space and correcting malalignment, comprising the steps of dissolving a quantity of growth hormone (somatotropin), preferably in purified form, in a buffer solution, and injecting one time or multiple repeat times, a single dosage of the mixture of purified growth hormone and buffer solution into the joint of a body so as to initiate the treatment process.

Claims

1. A method of treating inflammation in a joint of a body comprising the steps of:

a) dissolving a quantity of purified growth hormone in a buffer solution, and

b) injecting a single dosage of said growth hormone and said buffer solution into said joint along the joint surface.

2. A method of treating inflammation as recited in claim 1 wherein said buffer solution has a range of pH between generally about 5.5 and 8.3.

3. A method of treating inflammation as recited in claim 2 wherein said buffer solution is a phosphate buffer solution.

4. A method of treating inflammation as recited in claim 2 wherein said buffer solution is Hank'"'"'s Buffer Solution having a pH of about 8.0 to 8.3.

5. A method of treating inflammation as recited in claim 2 wherein said growth hormone is species specific so as to be identical to naturally produced growth hormones.

6. A method of treating inflammation as recited in claim 2 wherein said growth hormone is biologically engineered to assure maximum purity and disease elimination.

7. A method of treating inflammation as recited in claim 6 wherein a range of 0.5 to 10.0 milligrams of said purified growth hormone is dissolved in generally about 1 to 10 milliliters of said buffer solution, the total volume of said dosage being dependent upon the weight of the individual subject being injected, and the size of the joint.

8. A method of treating inflammation as recited in claim 6 wherein said single dosage is between generally about 0.025 to 0.249 milligrams of purified growth hormone per Kilogram of body weight.

9. A method of treating inflammation as recited in claim 6 wherein about 5.8 milligrams of said purified growth hormone is dissolved in 1 to 10 milliliters of said buffer solution.

10. A method of treating inflammation as recited in claim 9 further comprising the step of injecting a second one of said single dosage into the joint generally about one week later.

11. A method of treating inflammation as recited in claim 10 further comprising the steps of injecting a third one of said single dosage into the joint generally about one week later.

12. A method of treating inflammation as recited in claim 9 further comprising the steps of injecting a second one of said single dosage into the joint generally about two weeks later.

13. A method of treating inflammation as recited in claim 12 further comprising the steps of injecting a third one of said single dosage into the joint generally about two weeks later.

14. A method of treating inflammation as recited in claim 9 further comprising the step of injecting a second one of said single dosage into the joint generally about four weeks later.

15. A method of treating inflammation as recited in claim 14 further comprising the steps of injecting a third one of said single dosage into the joint generally about four weeks later.

16. A method of treating inflammation as recited in claim 1 further comprising the step of mixing generally about 0.5 milliliters to 10 milliliters of a local anesthetic with said mixture of growth hormone and buffer solution.

17. A method of treating inflammation as recited in claim 16 wherein the local anesthetic is Lidocaine.

18. A method of treating inflammation as recited in claim 1 further comprising the step of mixing between about 0.5 milliliter to 10 milliliters of Lidocaine with said mixture of growth hormone and buffer solution.

19. A method of increasing a patient'"'"'s range of motion of a joint comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.

20. A method of correcting a malalignment in an arthritic joint of a body, such as a bow-legged deformity, comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.

21. A method of increasing the space between the bone ends of a patient'"'"'s joint comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.

22. A method of smoothing the surface of the bone ends of a patient'"'"'s joint comprising the injection of at least a single dosage of a growth hormone in a range of 0.025 milligrams to 0.249 milligrams per kilogram of patient body weight dissolved in a buffer solution.

24. An anti-inflammatory composition as recited in claim 23 further comprising a local anesthetic.

25. An anti-inflammatory composition as recited in claim 23 further comprising an anti-protease agent.

26. An anti-inflammatory composition as recited in claim 23 further comprising an anti-enzyme agent.

28. An anti-inflammatory composition as recited in claim 27 further comprising a local anesthetic.

29. An anti-inflammatory composition as recited in claim 27 further comprising an anti-protease agent.

30. An anti-inflammatory composition as recited in claim 27 further comprising an anti-enzyme agent.

23. An anti-inflammatory composition comprising a purified growth hormone of between 0.025 milligrams to 0.249 milligrams per kilo of a patient'"'"'s body weight dissolved in a buffer solution of between 1 to 10 milliliters.

27. An anti-inflammatory composition comprising a purified growth hormone of between 0.5 milligrams to 10.0 milligrams per milliliter of a buffer solution.

31. An analgesic composition comprising a purified growth hormone of between 0.025 milligrams to 0.249 milligrams per kilo of a patient'"'"'s body weight dissolved in a buffer solution of between 1 to 10 milliliters.

32. An analgesic composition as recited in claim 31 further comprising a local anesthetic.

33. An analgesic composition as recited in claim 32 wherein said local anesthetic comprises Lidocain in an amount of generally between about 0.5 milliliter to 10 milliliters.

34. An analgesic composition as recited in claim 33 further comprising a local anesthetic agent.

35. An analgesic composition as recited in claim 33 further comprising an anti-protease agent.

36. An analgesic composition as recited in claim 33 further comprising an anti-enzyme agent.

37. An analgesic composition as recited in claim 31 further comprising an anti-protease agent.

38. An analgesic composition as recited in claim 31 further comprising an anti-enzyme agent.

39. An analgesic composition comprising a purified growth hormone of between 0.5 milligrams to 10.0 milligrams per milliliter of a buffer solution.